Surveillance Summary Feb 14 – Feb 20, 2004
February 29, 2004 by admin · Leave a Comment
Our surveillance program experienced light activity throughout Week 8 of 2004. A total of 20 technology updates were recorded; 2 of these were newly detected technologies added to our database (New Detects), while 18 updates were made to already existing technology records. This week’s average Health Technology Impact Score was 41.85, slightly above the 2004 average of 38. Cordis Corporation’s coronary artery stent CYPHER and Genentech’s Avastin are this week’s updated technologies in the High Impact Technology category.
Week at a Glance
Technologies updated this week in the BioHorizon database
Technology Company Target Disease Score CYPHER™ Cordis Coronary Artery Disease 86/100 Avastin™ Genentech Metastatic Lung Cancer 72/100 Indiplon Neurocrine Insomnia 54/100 Zidaxin Sciclone Hepatitis C 54/100 Periostat Collagenex Rosacea 50/100 MS-325 Epix Multiple Sclerosis 50/100 MyVax Genotope Non-Hodgkins Lmphoma 47/100 PT-141 Palatin Erectile Dysfunction 47/100 Gvax® Cell Genesys Non-Small Cell Lung Cancer 30/100 Ramoplanin Genome Therapeutics CDAD 30/100
